Hostname: page-component-586b7cd67f-2brh9 Total loading time: 0 Render date: 2024-11-30T21:12:25.476Z Has data issue: false hasContentIssue false
  • English
  • Français

RAGE and Aβ Immunoglobulins: Relation to Alzheimer’s disease-related cognitive function

Published online by Cambridge University Press:  05 May 2010

MEGHAN B. MITCHELL ,
JERRY J. BUCCAFUSCO ,
ROSANN F. SCHADE ,
SCOTT J. WEBSTER ,
SHYAMALA MRUTHINTI ,
DEAN U. HARRELL ,
NIDHI K. GULATI  and
L. STEPHEN MILLER
MEGHAN B. MITCHELL*
Affiliation:
Department of Psychology, University of Georgia, Athens, Georgia
JERRY J. BUCCAFUSCO
Affiliation:
Department of Pharmacology and Toxicology, Medical College of Georgia, Augusta, Georgia Department of Research, Charlie Norwood Veteran’s Affairs Medical Center, Augusta, Georgia
ROSANN F. SCHADE
Affiliation:
Department of Pharmacology and Toxicology, Medical College of Georgia, Augusta, Georgia Department of Research, Charlie Norwood Veteran’s Affairs Medical Center, Augusta, Georgia
SCOTT J. WEBSTER
Affiliation:
Department of Pharmacology and Toxicology, Medical College of Georgia, Augusta, Georgia
SHYAMALA MRUTHINTI
Affiliation:
Department of Pharmacology and Toxicology, Medical College of Georgia, Augusta, Georgia Department of Research, Charlie Norwood Veteran’s Affairs Medical Center, Augusta, Georgia
DEAN U. HARRELL
Affiliation:
Department of Internal Medicine, Medical College of Georgia, Augusta, Georgia
NIDHI K. GULATI
Affiliation:
Department of Family Medicine, Medical College of Georgia, Augusta, Georgia
L. STEPHEN MILLER
Affiliation:
Department of Psychology, University of Georgia, Athens, Georgia
*
*Correspondence and reprint requests to: Meghan Mitchell, Building 8, Room 1096, 200 Springs Road, Edith Nourse Rogers Memorial Veterans Hospital, Bedford, MA 01730. E-mail: [email protected]
Get access Rights & Permissions [Opens in a new window]

Abstract

The immunoglobulins (IgGs) for beta amyloid (Aβ) and receptors for the advanced glycation end products (RAGE) have previously been shown to be related to memory and language measures in a mixed neurological sample of older adults. In this study, we examined group differences in Aβ and RAGE IgGs, as well as the relationship between both IgGs and cognitive performance in nondiabetic older adults with normal cognition, mild cognitive impairment (MCI), and probable Alzheimer’s disease (AD). We found RAGE and Aβ levels to be elevated in some AD participants, leading to significant AD–control group differences. While there was an overall correlation between both IgG levels and global cognition across all three groups, this relationship was largely attributable to group differences in cognition, highlighted by considerable variability within groups in the relationship between IgG levels and cognition. While findings do not support a consistent relationship between cognition and either IgG, further research with larger samples is needed to better characterize cognitive differences between AD participants with high versus low Aβ and RAGE titers. (JINS, 2010, 16, 672–678.)

Keywords

BiomarkersDementiaEarly detectionMemory functionBlood testImmune system function
Type
Research Articles
Information
Journal of the International Neuropsychological Society , Volume 16 , Issue 4 , July 2010 , pp. 672 - 678
Copyright
Copyright © The International Neuropsychological Society 2010

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

REFERENCES

Alzheimer’s Association. (2008). Alzheimer’s disease facts and figures. Alzheimer’s and Dementia, 4, 2.Google Scholar
Berg, L., McKeel, D. W., Miller, P., Storandt, M., Rubin, E., Morris, J. C., et al. (1998). Clinicopathologic studies in cognitively healthy aging and Alzheimer disease. Archives of Neurology, 55, 326–335.CrossRefGoogle Scholar
Burke, W. J., Miller, J. P., Rubin, E. H., Morris, J. C., Coben, L. A., Duchek, J., et al. . (1988). Reliability of the Washington University Clinical Dementia Rating. Archives of Neurology, 45, 31–32.CrossRefGoogle ScholarPubMed
DeKosky, S. (2003). Early intervention is key to successful management of Alzheimer disease. Alzheimer Disease and Associated Disorders, 17, S99–S104.CrossRefGoogle ScholarPubMed
Emanuele, E., D’Angelo, A., Tomaino, C., Binetti, G., Ghidoni, R., Politi, P., et al. . (2005). Circulating levels of soluble receptor for advanced glycation end products in Alzheimer disease and vascular dementia. Archives of Neurology, 62, 1734–1736.CrossRefGoogle ScholarPubMed
McCulla, M. M., Coats, M., Van Fleet, N., Duchek, J., Grant, E., & Morris, J. C. (1989). Reliability of clinical nurse specialists in the staging of dementia. Archives of Neurology, 46, 1210–1211.CrossRefGoogle ScholarPubMed
Morris, J. C. (1993). The Clinical Dementia Rating (CDR): Current version and scoring rules. Neurology, 43, 2412–2414.CrossRefGoogle Scholar
Mruthinti, S., Buccafusco, J. J., Hill, W. D., Waller, J. L., Jackson, T. W., Zamrini, E. Y., & Schade, R. F. (2004). Autoimmunity in Alzheimer’s disease: Increased levels of circulating IgGs binding Aβ and RAGE peptides. Neurobiology of Aging, 25, 1023–1032.CrossRefGoogle ScholarPubMed
Mruthinti, S., Schade, R. F., Harrell, D. U., Gulati, N. K., Swamy-Mruthinti, S., Lee, G. P., & Buccafusco, J. J. (2006). Autoimmunity in Alzheimer’s disease as evidenced by plasma immunoreactivity against RAGE and Aβ42: Complication of diabetes. Current Alzheimer Research, 3, 229–235.CrossRefGoogle ScholarPubMed
Nath, A., Hall, E., Tuzova, M., Dobbs, M., Jones, M., Anderson, C., et al. . (2003). Autoantibodies to amyloid β-peptide (Aβ) are increased in Alzheimer’s disease patients and Aβ antibodies can enhance Aβ neurotoxicity. NeuroMolecular Medicine, 3, 29–39.CrossRefGoogle ScholarPubMed
Neeper, M., Schmidt, A. M., Brett, J., Yan, S. D., Wang, F., Pan, Y. C., et al. . (1992). Cloning and expression of cell surface receptor for advanced glycosylation end products of proteins. Journal of Biological Chemistry, 267, 4998–5004.CrossRefGoogle ScholarPubMed
Randolph, C. (1998). Repeatable Battery for the Assessment of Neuropsychological Status (RBANS). San Antonio, TX: The Psychological Corporation.Google ScholarPubMed
Randolph, C., Tierney, M., Mohr, E., & Chase, T. (1998). The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS): Preliminary clinical validity. Journal of Clinical and Experimental Neuropsychology, 20, 310–319.CrossRefGoogle Scholar
Wilson, J. S., Mruthinti, S., Buccafusco, J. J., Schade, R. F., Mitchell, M. B., Harrell, D. U., et al. . (2009). Anti-RAGE and Aβ immunoglobulin levels are related to dementia level and cognitive performance. Journals of Gerontology: Medical Sciences, 64A, 264–271.Google Scholar